Idiopathic Thrombocytopenic Purpura Therapeutics Market
PUBLISHED: 2024 ID: SMRC25930
SHARE
SHARE

Idiopathic Thrombocytopenic Purpura Therapeutics Market

Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecasts to 2030 - Global Analysis By Product (Anti-D Immunoglobulins, Corticosteroids, Intravenous Immunoglobulin (IVIG), Thrombopoietin Receptor Agonists (TPO-RA) and Other Products), Treatment Type, Mode of Administration, Distribution Channel, End User and By Geography

5.0 (67 reviews)
5.0 (67 reviews)
Published: 2024 ID: SMRC25930

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Idiopathic Thrombocytopenic Purpura Therapeutics Market is accounted for $649.1 million in 2023 and is expected to reach $1045.0 million by 2030 growing at a CAGR of 7.04% during the forecast period. Idiopathic Thrombocytopenic Purpura (ITP) is a disorder characterized by a low platelet count in the blood (thrombocytopenia) due to the immune system mistakenly attacking and destroying platelets. Platelets are crucial for blood clotting, and a reduced platelet count can lead to abnormal bleeding or bruising. Patients are at risk of bleeding complications, so therapies may include platelet transfusions or medications to promote clotting and prevent bleeding episodes.

According to WebMD LLC, in 2022, ITP affected adults at roughly 66 cases per 1,000,000 per year. Children's incidence is estimated to be 50 cases per 1,000,000 per year on average, and about 10 new instances of chronic refractory ITP are reported each year per million people.

Market Dynamics: 

Driver: 

Rising demand for combination therapies

The market is witnessing a surge in demand for combination therapies, driven by their enhanced efficacy and ability to target multiple pathways simultaneously. This trend is propelled by the growing understanding of the complex nature and the need for more comprehensive treatment approaches. Combination therapies offer synergistic benefits, improved patient outcomes, and are increasingly preferred by healthcare providers and patients alike, shaping the landscape of treatment strategies.

Restraint:

Side effects of treatments

Corticosteroids may cause weight gain, mood swings, and increased risk of infection. Immunoglobulins can lead to allergic reactions or headaches. Splenectomy poses risks of infection due to reduced immune function and increases the risk of blood clots. Monitoring for these side effects and managing them appropriately is crucial in the treatment of thrombocytopenic purpura. Thus, in the market, treatments like corticosteroids, immunoglobulins, and splenectomy can have side effects.

Opportunity:

Advances in treatment options

Novel therapies such as thrombopoietin receptor agonists (TPO-RAs) have emerged as effective agents for increasing platelet counts in ITP patients. Additionally, immunomodulatory drugs like rituximab and fostamatinib have shown promise in managing refractory cases. These developments reflect a growing understanding of ITP's pathophysiology and highlight the evolving landscape of targeted therapies for this hematologic disorder. Hence, these are the factors driving the growth of the market.

Threat:

High cost of treatment

Patients often struggle with the financial burden of therapies, including immunoglobulins, corticosteroids, and splenectomy. These expenses can deter individuals from seeking necessary medical care and adhering to treatment plans. Additionally, research and development costs for innovative therapies contribute to the overall high cost of managing thrombocytopenic purpura, posing a barrier to accessible healthcare for affected individuals.

Covid-19 Impact: 

The COVID-19 pandemic significantly impacted the Thrombocytopenic Purpura Therapeutics Market. Lockdowns and healthcare priorities diverted focus from non-emergency conditions, affecting diagnosis and treatment. Supply chain disruptions led to shortages of critical medications, impacting patient care and treatment outcomes. Clinical trials were also delayed, hindering the development of new therapies. However, increased awareness of healthcare preparedness and telemedicine adoption could drive innovation and resilience in managing Thrombocytopenic Purpura in the post-pandemic era.

The rituximab segment is expected to be the largest during the forecast period

The rituximab segment is expected to be the largest during the forecast period. Rituximab, a monoclonal antibody targeting CD20 on B cells, has emerged as a promising therapy for thrombocytopenic purpura (ITP). In the therapeutics market, its role lies in modulating immune response, particularly in refractory or relapsed cases where conventional treatments fail. Its efficacy in increasing platelet counts and reducing bleeding episodes has bolstered its adoption, contributing significantly to the evolving landscape of ITP management.

The ambulatory surgical centers  segment is expected to have the highest CAGR during the forecast period

The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period. They play a crucial role in the market by providing specialized care and procedures such as platelet transfusions and splenectomies. These centers offer a convenient and efficient setting for patients to receive treatment, contributing to improved patient outcomes and satisfaction. With advanced technologies and skilled medical professionals, 

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The market in the region is characterized by a diverse range of treatment options, including corticosteroids, intravenous immunoglobulins, and thrombopoietin receptor agonists. This market is driven by increasing awareness, advancements in medical technology, and a growing patient population. Additionally, ongoing research and development efforts contribute to the expansion of treatment modalities and improved outcomes for individuals in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Awareness and its treatment options has increased among healthcare professionals and patients, leading to early diagnosis and treatment. Pharmaceutical companies are collaborating with healthcare providers and research institutions in the region to develop and commercialize new treatments. Continuous research and development efforts aimed at improving treatment efficacy and safety are expected to further drive market growth in the region.

Key players in the market

Some of the key players in Idiopathic Thrombocytopenic Purpura Therapeutics market include Novartis, Pfizer, Sanofi, Amgen Inc., Johnson & Johnson, Takeda Pharmaceutical Company, GlaxoSmithKline, AbbVie, Teva Pharmaceutical Industries, Merck & Co., Bayer, Vertex Pharmaceuticals, FUJIFILM Holdings Corporation, Olympus Corporation, F. Hoffmann-La Roche Ltd, Medtronic, Eli Lilly and Company, GrifolsBiologicals  and Sun Pharmaceutical Industries Ltd.

Key Developments:

In January 2020, Novartis in association with The ITP Support Association announced the launch of ITP Pocket Log, designed to help people manage and track their ITP on the move, which is available on Google Play and Apple App Store.

In January 2019, GrifolsBiologicals Inc. announced that it has entered into a license agreement with the US-based biotechnology company Rigel Pharmaceuticals to commercialize fostamatinib disodium hexahydrate in all potential future indications in Europe and Turkey.

Products Covered:
• Anti-D Immunoglobulins
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Thrombopoietin Receptor Agonists (TPO-RA)
• Other Products

Treatment Types Covered:
• Splenectomy
• Rituximab
• Immunosuppressants 
• Other Treatment Types 

Mode of Administrations Covered:
• Oral
• Intravenous 
• Subcutaneous 
• Intramuscular 

Distribution Channels Covered:
• Pharmaceutical Companies
• Distributors
• Retail Pharmacies
• Online Pharmacies 

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals
• Clinics
• Other End Users 

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary       
         
2 Preface        
 2.1 Abstract       
 2.2 Stake Holders      
 2.3 Research Scope      
 2.4 Research Methodology     
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources    
  2.5.2 Secondary Research Sources    
  2.5.3 Assumptions     
         
3 Market Trend Analysis      
 3.1 Introduction      
 3.2 Drivers       
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats       
 3.6 Product Analysis      
 3.7 End User Analysis      
 3.8 Emerging Markets      
 3.9 Impact of Covid-19      
         
4 Porters Five Force Analysis      
 4.1 Bargaining power of suppliers     
 4.2 Bargaining power of buyers     
 4.3 Threat of substitutes     
 4.4 Threat of new entrants     
 4.5 Competitive rivalry      
         
5 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product 
 5.1 Introduction      
 5.2 Anti-D Immunoglobulins     
 5.3 Corticosteroids      
 5.4 Intravenous Immunoglobulin (IVIG)    
 5.5 Thrombopoietin Receptor Agonists (TPO-RA)   
 5.6 Other Products      
         
6 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Treatment Type
 6.1 Introduction      
 6.2 Splenectomy      
 6.3 Rituximab      
 6.4 Immunosuppressants      
 6.5 Other Treatment Types     
         
7 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Mode of Administration
 7.1 Introduction      
 7.2 Oral       
 7.3 Intravenous       
 7.4 Subcutaneous       
 7.5 Intramuscular       
         
8 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Distribution Channel
 8.1 Introduction      
 8.2 Pharmaceutical Companies     
 8.3 Distributors      
 8.4 Retail Pharmacies      
 8.5 Online Pharmacies      
         
9 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By End User 
 9.1 Introduction      
 9.2 Ambulatory Surgical Centers     
 9.3 Hospitals       
 9.4 Clinics       
 9.5 Other End Users      
         
10 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Geography 
 10.1 Introduction      
 10.2 North America      
  10.2.1 US      
  10.2.2 Canada      
  10.2.3 Mexico      
 10.3 Europe       
  10.3.1 Germany      
  10.3.2 UK      
  10.3.3 Italy      
  10.3.4 France      
  10.3.5 Spain      
  10.3.6 Rest of Europe     
 10.4 Asia Pacific      
  10.4.1 Japan      
  10.4.2 China      
  10.4.3 India      
  10.4.4 Australia      
  10.4.5 New Zealand     
  10.4.6 South Korea     
  10.4.7 Rest of Asia Pacific     
 10.5 South America      
  10.5.1 Argentina     
  10.5.2 Brazil      
  10.5.3 Chile      
  10.5.4 Rest of South America    
 10.6 Middle East & Africa     
  10.6.1 Saudi Arabia     
  10.6.2 UAE      
  10.6.3 Qatar      
  10.6.4 South Africa     
  10.6.5 Rest of Middle East & Africa    
         
11 Key Developments       
 11.1 Agreements, Partnerships, Collaborations and Joint Ventures  
 11.2 Acquisitions & Mergers     
 11.3 New Product Launch     
 11.4 Expansions      
 11.5 Other Key Strategies     
         
12 Company Profiling       
 12.1 Novartis       
 12.2 Pfizer       
 12.3 Sanofi       
 12.4 Amgen Inc.      
 12.5 Johnson & Johnson      
 12.6 Takeda Pharmaceutical Company    
 12.7 GlaxoSmithKline      
 12.8 AbbVie       
 12.9 Teva Pharmaceutical Industries    
 12.10 Merck & Co.      
 12.11 Bayer       
 12.12 Vertex Pharmaceuticals     
 12.13 FUJIFILM Holdings Corporation    
 12.14 Olympus Corporation     
 12.15 F. Hoffmann-La Roche Ltd     
 12.16 Medtronic      
 12.17 Eli Lilly and Company     
 12.18 GrifolsBiologicals       
 12.19 Sun Pharmaceutical Industries Ltd.    
         
List of Tables        
1 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Region (2021-2030) ($MN)
2 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Product (2021-2030) ($MN)
3 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Anti-D Immunoglobulins (2021-2030) ($MN)
4 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Corticosteroids (2021-2030) ($MN)
5 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Intravenous Immunoglobulin (IVIG) (2021-2030) ($MN)
6 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Thrombopoietin Receptor Agonists (TPO-RA) (2021-2030) ($MN)
7 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
8 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Treatment Type (2021-2030) ($MN)
9 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Splenectomy (2021-2030) ($MN)
10 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Rituximab (2021-2030) ($MN)
11 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Immunosuppressants  (2021-2030) ($MN)
12 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Other Treatment Types (2021-2030) ($MN)
13 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Mode of Administration (2021-2030) ($MN)
14 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
15 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Intravenous  (2021-2030) ($MN)
16 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Subcutaneous  (2021-2030) ($MN)
17 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Intramuscular  (2021-2030) ($MN)
18 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
19 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Distributors (2021-2030) ($MN)
20 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Hospital pharmacies (2021-2030) ($MN)
21 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Retail pharmacies (2021-2030) ($MN)
22 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Online pharmacies (2021-2030) ($MN)
23 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By End User (2021-2030) ($MN)
24 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Ambulatory surgical centers (2021-2030) ($MN)
25 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
26 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Clinics (2021-2030) ($MN)
27 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
         
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials